Actinium Pharmaceuticals Inc
$ 1.45
0.00%
04 Dec - close price
- Market Cap 45,234,000 USD
- Current Price $ 1.45
- High / Low $ 1.54 / 1.41
- Stock P/E N/A
- Book Value 0.44
- EPS -1.11
- Next Earning Report 2026-03-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -1.33 %
- 52 Week High 2.41
- 52 Week Low 1.03
About
Actinium Pharmaceuticals, Inc. is a leading clinical-stage biopharmaceutical firm focused on developing cutting-edge therapies for bone marrow transplantation and adoptive cell therapies, with a primary emphasis on hematologic malignancies. Based in New York, the company is advancing its proprietary antibody-radionuclide conjugate platform, aimed at improving patient outcomes in both transplantation and cancer care. With a promising pipeline of therapeutic candidates and strategic collaborations, Actinium is well-positioned to tackle significant unmet medical needs in the oncology sector, making it a compelling prospect for institutional investors seeking innovation in biopharmaceuticals.
Analyst Target Price
$5.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-24 | 2025-08-08 | 2025-04-24 | 2025-03-27 | 2024-10-31 | 2024-08-05 | 2024-04-26 | 2024-03-29 | 2023-11-02 | 2023-08-14 | 2023-05-15 | 2023-03-31 |
| Reported EPS | -0.16 | -0.22 | -0.51 | -0.21 | -0.37 | -0.38 | -0.31 | -0.34 | -0.49 | -0.58 | -0.43 | -0.43 |
| Estimated EPS | -0.3175 | -0.348 | -0.2775 | -0.39 | -0.3667 | -0.4 | -0.52 | -0.54 | -0.53 | -0.48 | -0.42 | -0.35 |
| Surprise | 0.1575 | 0.128 | -0.2325 | 0.18 | -0.0033 | 0.02 | 0.21 | 0.2 | 0.04 | -0.1 | -0.01 | -0.08 |
| Surprise Percentage | 49.6063% | 36.7816% | -83.7838% | 46.1538% | -0.8999% | 5% | 40.3846% | 37.037% | 7.5472% | -20.8333% | -2.381% | -22.8571% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-13 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2175 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATNM
2025-11-04 07:30:00
Actinium Pharmaceuticals will present new preclinical data for its ATNM-400 program at the 2025 San Antonio Breast Cancer Symposium, showcasing its anti-tumor activity in hormone-resistant and HER2-resistant breast cancer. This expands ATNM-400's pan-tumor profile across three solid tumor indications, including prostate cancer and non-small cell lung cancer (NSCLC). The data highlights ATNM-400's potential as a monotherapy, in combination, or as an alternative therapy for significant unmet needs in these high-value cancer segments.
2025-11-03 08:30:00
Actinium Pharmaceuticals, Inc. announced that its Chairman and CEO, Sandesh Seth, will participate in the Stephens Biotechnology Virtual Fireside Chat Conference on November 4, 2025. Management will also be available for one-on-one investor meetings. The company will discuss its lead product candidate ATNM-400 for prostate cancer and NSCLC, and Actimab-A for AML and other myeloid malignancies.
2025-10-24 08:30:00
Actinium Pharmaceuticals presented new preclinical data for ATNM-400, a novel Actinium-225 radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat. The data demonstrated ATNM-400's potent and durable efficacy against prostate cancer, including in models resistant to current standard-of-care treatments like enzalutamide and 177Lu-PSMA-617, and its potential for use as a monotherapy, in combination regimens, and in patients relapsing after other treatments. The therapy shows strong mechanistic synergy and is being explored for efficacy in non-small cell lung cancer as well.
2025-10-15 15:31:39
Maxim Group analyst Jason McCarthy has reiterated a Buy rating on Actinium Pharmaceuticals with a $5.00 price target, citing the company's strong pipeline and strategic developments. Actinium's ATNM-400 candidate shows promise in treating resistant non-small cell lung cancer and prostate cancer, while Actimab-A for acute myeloid leukemia is also progressing. The company's innovative use of Actinium-225 for targeted radiotherapy, coupled with commercialization plans, underpins the positive outlook.
2025-10-13 17:14:42
Actinium Pharmaceuticals (ATNM) announced promising preclinical results for its ATNM-400 program, an Actinium-225 antibody radioconjugate, targeting non-small cell lung cancer (NSCLC). The ATNM-400 demonstrated efficacy in EGFR-mutant NSCLC models and the ability to overcome osimertinib resistance, and enhance its effectiveness in combination, offering a potential breakthrough for patients with limited treatment options. Despite strong liquidity, the biotechnology company faces financial distress indicators like negative profitability and low Piotroski F-Score, reflecting ongoing R&D investment without immediate returns.
2025-10-13 17:14:42
Actinium Pharmaceuticals (ATNM) announced promising preclinical data for its ATNM-400 program, an Actinium-225 antibody radioconjugate, targeting non-small cell lung cancer (NSCLC). This treatment shows potential to overcome resistance to current EGFR tyrosine kinase inhibitors like osimertinib, a significant advancement for patients with limited treatment options. The company, focused on radiotherapies for cancer, plans to present these findings at the AACR-NCI-EORTC International Conference.
